BLUDE Immucor (MM)

Lasky & Rifkind, Ltd., a law firm with offices in New York and Chicago, announces that a lawsuit has been filed in the United States District Court for the Northern District of Georgia, on behalf of persons who purchased or otherwise acquired publicly traded securities of Immucor, Inc. ("Immucor" or the "Company") (NASDAQ:BLUDE) between January 7, 2005 and August 29, 2005, inclusive, (the "Class Period"). The lawsuit was filed against Immucor, Dr. Gioacchino De Chirico, Steven C. Ramsey and Edward L. Gallup ("Defendants"). If you are a member of this class and wish to view a copy of a complaint and join this class action, please e-mail us at investorrelations@laskyrifkind.com and request a copy of the complaint and a plaintiff certification. If you are a member of the Class, you may move the Court no later than October 31, 2005 to serve as a lead plaintiff for the Class. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. However, if you choose to remain an absent class member, unless and until a class is certified, you are not represented by counsel. The complaint alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically, the complaint alleges that Defendants misrepresented that the Company's financial statements and disclosures fairly and accurately reflected the Company's results from operations as required by Generally Accepted Accounting Principles ("GAAP"). On August 26, 2005, the Company was forced to announce that the SEC had launched a formal investigation into payments made by its Italian unit and its President, Mr. De Chirico, in October 2003 to a physician connected with a hospital with which the Company was doing business. Then, after the market closed on August 29, 2005, the Company indicated in a press release that it would be revising its previously issued results for at least two quarters in order to account for previously unrecorded accrued bonuses. In reaction to the news, Immucor's common stock price fell from $28.61 on August 25, 2005 to close at $24.00 on August 20, 2005. If you bought Immucor securities between January 7, 2005 and August 29, 2005, inclusive, and would like to obtain information about the lawsuit, then you are invited to call (800) 495-1868 to speak with an advisor.